Genistein
description1
description2
Specification
Test Items |
Standard |
Genistein (CAS:446-72-0) |
98% by HPLC |
Loss on drying |
≤1.0% |
Residue on ignition |
≤1.0% |

Natural Sources

Dual Activity

High Safety
1.Molecular Target Network
2.Pharmacokinetics
Absorption
Low oral bioavailability (<10%), metabolized by gut microbiota.
Distribution
High in liver/lungs/breast; poor BBB penetration (<1%).
Metabolism
Hepatic glucuronidation (UGT1A1/1A9), hydroxylation (CYP1A2).
Excretion
Primarily biliary (80%), urinary excretion <5%
Clinical Applications
Indication |
Mechanism |
Stage |
Breast Cancer Adjuvant |
ERβ agonism + anti-angiogenesis |
Phase II |
Menopausal Symptoms |
Phytoestrogenic effects |
Marketed (supplement) |
Osteoporosis |
Osteoblast differentiation |
Phase I |

Anticancer

Menopause

Dietary Supplement
Safety Evaluation
Adverse Reactions
System |
Incidence |
Manifestations |
Gastrointestinal |
5% |
Mild nausea |
Endocrine |
<1% |
Estrogenic effects |
Hypersensitivity |
Rare |
Rash |
Drug Interactions
CYP1A2 Substrates (e.g., caffeine): Metabolism slowed (AUC↑30%).
Tamoxifen: Potential antagonism of anti-estrogen effects.
Research Progress Green max
Novel Formulations
Nanoemulsions: Bioavailability increased to 35%.
Transdermal Patches: For localized estrogen therapy.
New Indications
Alzheimer’s Disease: Reduces Aβ deposition (animal models).
Diabetic Nephropathy: Inhibits TGF-β/Smad pathway.
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.


